Introduction
In postmenopausal women, the incidence and prevalence of cardiovascular disease (CVD) are increased, 1 a pathological process possibly related to the decrease in estrogen levels after the cessation of ovarian function. 2, 3 Dyslipidemia is one the most important risk factor for CVD, which can be corrected and prevented. In prospective randomized clinical trials conducted mostly in older women, menopause hormone therapy (MHT) showed that not only they do not offer protection against CVD, but they can even increase the risk of this disease. 4, 5 However, more recent studies suggest that MHT is associated with beneficial effects with regard to CVD when the therapy is initiated close to menopause but not when it is initiated later. 4 Estrogen administrations is still the most effective treatment for the symptoms of menopausal and to prevent osteoporosis, in concordance to increase the health and quality of postmenopausal women' s life. 5 Balancing the risk versus beneficial factors of MTH, some women opt for natural forms of treatment. Phytoestrogens are a diverse group of non-steroidal substances of plant origin that are structurally similar to estradiol and have an affinity for estrogens receptors (ERs), 6 ERα, and ERβ, producing estrogenic and antiestrogenic effects. 7 
Laboratory measurements
Total plasma cholesterol (TC), High-density lipoproteincholesterol (HDL-C), and total triacylglycerols (TG) were quantified by commercially available kits (Sigma Diagnostics, St Louis, MO, USA). Low-density lipoproteins-cholesterol (LDL-C) was calculated by using the Friedewald equation.
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Morning fasting blood samples were collected from all subjects on an assigned date. Serum P-selectin and sCD40L
were quantified using an ELISA kit (R&D System, In Minneapolis reactive, MN, USA). Assay was carried out on diluted samples following manufacturer' s instructions.
Measurement soluble CD40L was determined according to the methodology described by Allanore et al. This decrease in Apo-B levels was also significant between groups (P = 0.047).
In the case of women who received ISO, we tested the hypothesis that ISO-supplement on cardiovascular risk factors in the postmenopause may be associated with the age of the woman. The effect of ISO on lipoprotein profiles and inflammation markers among subgroups (women ＜65 years old, and women ＞65 years old) is shown in Table 2 . Within sub-group ＜65 years, ISO-supplement caused a significant decrease in TC (P = 0.007), LDL-C (P = 0.013) and sCD40L
(P = 0.016). However, within sub-group ＞65 years, ISOsupplement has no effect on plasma lipid levels, but was observed a significant decrease in Apo-B (P = 0.028).
Discussion
The aim of the present double-blind, randomized placebocontrolled study was to analyze the effect of supplementation of soy-ISO over 12 weeks on the lipid profile, apolipoprotein and inflammation markers in postmenopausal women (55-72 Dyslipidemia is a well-studied cardiovascular risk factor and the onset of menopause increase blood level of TC, TG and LDL-C, and increased as well LDL-C /HDL-C ratio and TC/HDL-C ratio. 20, 21 Reports demonstrate that the estrogen action on lipid variations would be dependent on aging. In fact, several studies suggest that estrogen therapy is related to favorable effect cardiovascular risk factor when the treatment is initiated close to the time of menopause. 22, 23 ISO are natural substances that are found in a wide range of plants kingdom species, and that weakly bind to ERs.
There are 2 types of ERs: ERα and ERβ. ISO can bind to either ERα or ERβ; however, ISO appears to have a higher affinity for ERβ. 24 The activation of ERs by ISO is selective, that means that in some tissues act like estrogen and in others, as anti-estrogens. 25 Therefore, studies in postmenopausal women have shown that soy protein and ISO reduces serum TC and LDL-C, and increase HDL-C concentration.
However, given the inconsistency of these results, the action of soy-ISO on lipid profile is controversial. 26 The results of our study may explain, in part, this inconsistency since Inflammation is a central process to CVD, and in this aspect platelets play crucial roles. The CD40-CD40L is as considered as a pro-inflammatory marker and has been identified on several cells, however the majority of the circulating levels (~95%) comes from platelets. 29 Platelets express CD40L on their cell membrane upon activation, and CD40L The data is presented as mean ± standard deviation. P values calculated using the Wilcoxon signed-rank test. 
Conclusion
In summary, our results may further contribute to the understanding of the physiological impact of the epidemiological finding that soy-ISO decreases the risk of CVD.
The results of this investigation show that the effect of supplementation of ISO, at the dose of 100 mg/day, did no significantly exert a favorable effect on the lipid profile and CD40-CD40L system in postmenopausal women. However, a subgroup analysis suggests that effect of supplementation of ISO on lipid variable and inflammatory marker is age dependent, and is observed only in postmenopause women younger than 64 years. 
